‘Surgical pathology’ : what’s in a name? by Cilia Vincenti, Albert
the American name for ‘histopathology’ (also known as ‘cellular’, ‘tissue’ or ‘anatomic’ pathology) is ‘surgical pathology’, and there is medical history behind this label. 
In the 19th century, big American surgical departments were 
increasingly dissatisfied with reports from pathology colleagues. 
Surgeons were mainly interested in prognosis after excision 
of a diseased tissue or organ, and not in detailed microscopic 
descriptions devoid of any clinically useful information. They 
eventually decided that the pathological examination of their 
surgical specimens would be carried out in-house. This is 
why, in some of the larger American institutions, the surgical 
pathology department, including the frozen section room, is 
located within the surgical department. 
These ‘novel concept’ surgical pathology departments 
immediately set about researching morphological clues to 
prognosis which, in the main, consisted of painstaking patient 
follow-up and histology review. One important breakthrough 
of this research was the identification of a group of pseudo-
sarcomatous lesions. These mimicked sarcoma both clinically 
and microscopically. However, these pseudo-sarcomatous 
lesions had been responsible for many unnecessary limb 
amputations.
In the mid-1960s a Maltese medical student was suffering 
from a recurrent tumour in his right leg’s peroneal compartment 
muscles, which was diagnosed as fibrosarcoma. He struck 
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it lucky when his Maltese surgeon declined to perform the 
indicated amputation himself and referred him to London’s 
Royal Marsden Hospital (previously called The Royal Cancer 
Hospital).  
His luck consisted in that the pathologist at the Royal 
Marsden had just seen a paper by Arthur Purdy Stout, an 
American surgical pathologist, describing a number of pseudo-
sarcomas, including a so-called “desmoid” tumour (now 
classified as ‘infiltrative fibromatosis’), and how to distinguish 
them microscopically from sarcoma. The paper detailed how 
these lesions were locally infiltrative like sarcoma but did not 
metastasize. Most of them occurred in the anterior abdominal 
wall muscles in women, apparently after pregnancy, and in limb 
muscles in both sexes, predominantly in the young, with a high 
recurrence rate after attempts at local excision, and a tendency 
not to recur further after increasing age.
The Maltese student had first noticed his leg tumour in his 
late teens and in total, had undergone four attempts at excising 
it, twice in Malta and twice in London. The latter two operations 
involved block dissections of lateral calf muscles, including 
excision of the fibula with the whole peroneal compartment 
muscles in the first of these operations. Recurrence did not 
occur after the fourth operation when he reached age 25. Many 
other young people have been spared limb amputations by the 
clinical research of American surgical pathologists. 
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